98664-63-2Relevant academic research and scientific papers
INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH
-
Page/Page column 168-169, (2010/11/28)
Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula (I) and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R1, R2, R3, R4, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.
NOVEL APPLICATIONS OF THE MODIFIED POLONOVSKI REACTION -VIII SYNTHETIC STUDIES IN THE PSEUDOVINCAMINE SERIES
Jokela, Reija,Schueller, Siv,Lounasmaa, Mauri
, p. 1751 - 1757 (2007/10/02)
18-ethyl-(2'-methoxycarbonyl)-3α-ethyloctahydro-1,2,3,4,6,7,12,12b-indoloquinolizine 7, a potential intermediate in the pseudovincamine series, was synthesized via modified Polonovski reaction.Conformational considerations are presented.
